Supplemental material
Journal of Medical Economics
Volume 25, 2022 - Issue 1
Open access
10,065
Views
10
CrossRef citations to date
0
Altmetric
COVID-19
Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States
Manuela Di Fuscoa Health Economics & Outcomes Research, Pfizer Inc, New York, NY, USACorrespondence[email protected]
https://orcid.org/0000-0003-0079-7331
Kinga Marczellb Evidence, Value & Access by PPD, Evidera, Budapest, Hungary
, Kristen A. Degerc Modeling and Simulation, Evidera, Bethesda, USA
, Mary M. Morand Evidera PPD, Ivry-sur-Seine, France
, Timothy L. Wiemkend Evidera PPD, Ivry-sur-Seine, France
, Alejandro Canea Health Economics & Outcomes Research, Pfizer Inc, New York, NY, USA
, Solène de Boisvilliersb Evidence, Value & Access by PPD, Evidera, Budapest, Hungary
, Jingyan Yanga Health Economics & Outcomes Research, Pfizer Inc, New York, NY, USA;e Institute for Social and Economic Research and Policy, Columbia University, New York, NY, USA
, Shailja Vaghelaf HEOR, HealthEcon Consulting, Inc, Ancaster, ON, Canada
& Julie Roizg Evidence, Value & Access by PPD, Evidera, London, UK
show all
Pages 605-617
|
Received 04 Apr 2022, Accepted 25 Apr 2022, Published online: 15 May 2022
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.